A Two-part, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Single Doses of MMV533, Including a Pilot Food Evaluation in Healthy Participants.
Latest Information Update: 22 Oct 2024
At a glance
- Drugs SAR 441121 (Primary)
- Indications Malaria
- Focus Adverse reactions; First in man
Most Recent Events
- 03 Nov 2022 Status changed from recruiting to completed.
- 03 Aug 2022 Planned End Date changed from 30 May 2022 to 30 Sep 2022.
- 03 Aug 2022 Planned primary completion date changed from 3 May 2022 to 20 Sep 2022.